Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT05594043 2025-06-19

MK-6598-001

Phase 1 Completed

90 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04317066 2025-04-06

KEYNOTE-A33

Phase 1 Completed

7 enrolled 13 charts

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell

NCT03374254 2024-11-21

KEYNOTE-651

Phase 1 Completed

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05382325 2024-11-14

MK-1484-001

Phase 1 Active not recruiting

70 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04135352 2024-11-12

V938-001

Phase 1 Terminated

35 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasm Metastasis

NCT03833427 2024-11-07

MK-5618-001

Phase 1 Terminated

32 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03666273 2024-05-28

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Phase 1 Completed

60 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02054806 2023-10-30

MK-3475-028

Phase 1 Completed

477 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02835690 2022-10-26

MK-3475-032

Phase 1 Completed

44 enrolled 24 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03739138 2022-02-28

MK-4621-002

Phase 1 Terminated

30 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT02622074 2020-09-10

KEYNOTE 173

Phase 1 Completed

60 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT01295827 2019-12-13

KEYNOTE-001

Phase 1 Completed

1,260 enrolled 45 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT03099161 2019-06-05

MK-3814A-062

Phase 1 Terminated

10 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

Clinical Trials

MK-0472-001

MK-3475A-C18

MK-6837-001

TroFuse-008

MK-1454-001

KEYVIBE-001

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

MK-3475-A17

MK-6598-001

KEYNOTE-A33

KEYNOTE-651

MK-1484-001

V938-001

MK-5618-001

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

MK-3475-028

MK-3475-032

MK-4621-002

KEYNOTE 173

KEYNOTE-001

MK-3814A-062